Trial Profile

A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Gemcitabine; Oxaliplatin; Rituximab; Tocilizumab
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use
Acronyms SUNMO
Sponsors Roche

14 Feb 2025 Planned End Date changed from 1 Feb 2027 to 28 Feb 2027.
14 Feb 2025 Planned primary completion date changed from 1 Feb 2025 to 30 May 2025.
19 Sep 2024 Planned End Date changed from 30 Nov 2027 to 1 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com